SiBone $SIBN Shares Bought by Peregrine Capital Management LLC

Peregrine Capital Management LLC grew its position in SiBone (NASDAQ:SIBN) by 13.0% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 428,061 shares of the company’s stock after acquiring an additional 49,270 shares during the quarter. Peregrine Capital Management LLC owned approximately 0.97% of SiBone worth $5,406,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in SIBN. ANTIPODES PARTNERS Ltd acquired a new position in SiBone in the fourth quarter worth $29,000. Royal Bank of Canada raised its holdings in shares of SiBone by 98.5% during the fourth quarter. Royal Bank of Canada now owns 1,483 shares of the company’s stock worth $29,000 after purchasing an additional 736 shares during the period. Caitong International Asset Management Co. Ltd raised its holdings in shares of SiBone by 64,700.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,944 shares of the company’s stock worth $38,000 after purchasing an additional 1,941 shares during the period. Kemnay Advisory Services Inc. acquired a new stake in shares of SiBone during the fourth quarter worth $53,000. Finally, State of Wyoming bought a new position in shares of SiBone in the 2nd quarter worth about $55,000. 98.11% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other SiBone news, SVP Michael A. Pisetsky sold 3,726 shares of the business’s stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $14.63, for a total transaction of $54,511.38. Following the completion of the transaction, the senior vice president directly owned 280,509 shares of the company’s stock, valued at $4,103,846.67. The trade was a 1.31% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Jeffrey W. Dunn sold 3,575 shares of the company’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $15.25, for a total transaction of $54,518.75. Following the completion of the transaction, the director owned 16,057 shares of the company’s stock, valued at approximately $244,869.25. This trade represents a 18.21% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 29,875 shares of company stock valued at $437,666. 4.00% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research analysts have recently commented on the stock. Wall Street Zen lowered shares of SiBone from a “buy” rating to a “hold” rating in a report on Saturday, April 18th. Truist Financial reiterated a “buy” rating and set a $18.00 price objective (down from $20.00) on shares of SiBone in a research note on Tuesday, May 12th. Finally, TD Cowen cut their target price on shares of SiBone from $22.00 to $18.00 and set a “buy” rating on the stock in a report on Tuesday, May 12th. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, SiBone currently has a consensus rating of “Moderate Buy” and an average target price of $23.00.

SiBone Price Performance

Shares of NASDAQ SIBN opened at $16.80 on Thursday. SiBone has a 1-year low of $11.48 and a 1-year high of $21.89. The company has a debt-to-equity ratio of 0.20, a current ratio of 9.99 and a quick ratio of 8.34. The business’s fifty day moving average price is $14.57 and its two-hundred day moving average price is $15.52. The firm has a market capitalization of $745.08 million, a PE ratio of -43.08 and a beta of 0.67.

SiBone (NASDAQ:SIBN) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.07. The company had revenue of $52.59 million during the quarter, compared to the consensus estimate of $51.16 million. SiBone had a negative net margin of 8.10% and a negative return on equity of 9.56%. On average, research analysts expect that SiBone will post -0.44 EPS for the current year.

SiBone Profile

Si-BONE, Inc is a commercial?stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA?cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.